Results 21 to 30 of about 16,189 (104)

Crystal Structures of Large-Volume Commercial Pharmaceuticals [PDF]

Structural Dynamics
As part of a continuing project, the room-temperature crystal structures of 17 commercial pharmaceutical APIs have been solved and refined using synchrotron X-ray powder diffraction data (11-BM at APS and Wiggler Low Energy Beamline at CLS), and ...
James A Kaduk, Anja Dosen, Thomas N Blanton   +2 more
doaj   +2 more sources

Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis [PDF]

Neurology and Therapy, 2022
Mita Kuchimanchi
exaly   +2 more sources

Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation. [PDF]

PLoS One
Inflammation and oxidative stress contribute significantly to tissue damage in multiple sclerosis. Fumaric acid esters such as Dimethyl fumarate and Diroximel fumarate (DRF) exhibit immunomodulatory and antioxidative properties, although their mechanisms
Freudenstein D, Schneeweiss A, Krenz A, Gold R, Linker R, Haase S.   +5 more
europepmc   +2 more sources

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews [PDF]

Advances in Therapy, 2022
Sai L Shankar, Shivani Kapadia
exaly   +2 more sources

18 kDa Translocator protein (TSPO) is upregulated in rat brain after peripheral nerve injury and downregulated by diroximel fumarate. [PDF]

Brain Behav Immun
Neuroimmune signaling is a key process underlying neuropathic pain. Clinical studies have demonstrated that 18 kDa translocator protein (TSPO), a putative marker of neuroinflammation, is upregulated in discrete brain regions of patients with chronic pain.
Cazuza RA, Zagrai SM, Grieco AR, Avery TD, Abell AD, Wey HY, Loggia ML, Grace PM.   +7 more
europepmc   +2 more sources

Diroximel Fumarate Acts Through Nrf2 to Attenuate Methylglyoxal-Induced Nociception in Mice and Decrease ISR Activation in DRG Neurons. [PDF]

Diabetes
Diabetic neuropathic pain is associated with elevated plasma levels of methylglyoxal (MGO). MGO is a metabolite of glycolysis that causes pain hypersensitivity in mice by stimulating the phosphorylation of eukaryotic initiation factor 2α (p-eIF2α) and ...
Yousuf MS, Mancilla Moreno M, Woodall BJ, Thakur V, Li J, He L, Arjarapu R, Royer D, Zhang J, Chattopadhyay M, Grace PM, Price TJ.   +11 more
europepmc   +2 more sources

New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series [PDF]

Multiple Sclerosis Journal
John Kramer, Megan Schneider
exaly   +2 more sources

Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study. [PDF]

Int J Mol Sci
Diroximel fumarate (DRF) is an orally administered prodrug used in multiple sclerosis (MS) treatment. Although it exhibits better gastrointestinal (GI) tolerability than its analogues, many patients still discontinue therapy due to frequent GI adverse ...
Santonocito D, Greco G, Sarpietro MG, Schoubben A, Sciacca C, Romeo G, Mangano K, Puglia C.   +7 more
europepmc   +2 more sources

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. [PDF]

CNS Drugs, 2020
BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF).
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS, EVOLVE-MS-2 Study Group.   +16 more
europepmc   +2 more sources

Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design

Biomedicines, 2023
Alzheimer’s Disease (AD) is a debilitating disease that leads to severe cognitive impairment and functional decline. The role of tau hyperphosphorylation and amyloid plaque deposition in the pathophysiology of AD has been well described; however ...
Robert Sharkus, Richa Thakkar, Dennis L. Kolson, Cris S. Constantinescu   +3 more
doaj   +1 more source